Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Department of Psychiatry, Weill Medical College of Cornell University and New York Presbyterian Hospital, Westchester Division, White Plains, NY, USA.
Acta Psychiatr Scand. 2018 Sep;138(3):267-273. doi: 10.1111/acps.12937. Epub 2018 Jun 29.
We conducted a 12-week double-blind study of stabilization pharmacotherapy in patients with remitted psychotic depression (PD).
Seventy-one persons aged 18 years or older who had achieved remission of PD when randomized to either olanzapine plus sertraline or olanzapine plus placebo were continued on the double-blind treatment associated with remission. Symptoms of depression and psychosis, and weight, were measured once every 4 weeks. Cholesterol, triglycerides, and glucose were measured at stabilization phase baseline and Week 12/termination.
The effect of treatment did not significantly change with time for depression, weight, or metabolic measures in the stabilization phase. Eight of the 71 participants (11.3%; 95% CI: 5.8, 20.7) experienced a relapse of major depression, psychosis, or both. Treatment groups did not differ in the frequency of relapse. In the entire study group, the adjusted estimate for change in weight was an increase of 1.66 kg (95% CI: 0.83, 2.48) and the adjusted estimate for change in total cholesterol was a decrease of 14.8 mg/dL (95% CI: 3.5, 26.1) during the 12-week stabilization phase; the remaining metabolic measures did not significantly change.
Continuation of acute treatment was associated with stability of remission.
我们进行了一项为期 12 周的双盲研究，旨在观察稳定期精神分裂后抑郁（PD）患者的药物治疗情况。
71 名年龄在 18 岁或以上的患者在随机分为奥氮平+舍曲林或奥氮平+安慰剂组后，达到 PD 缓解，继续进行与缓解相关的双盲治疗。每 4 周测量一次抑郁和精神病症状以及体重。在稳定期基线和第 12 周/结束时测量胆固醇、甘油三酯和葡萄糖。
在稳定期，治疗对抑郁、体重或代谢指标的影响没有随时间而显著变化。71 名参与者中的 8 名（11.3%；95%CI：5.8，20.7）经历了重性抑郁、精神病或两者的复发。治疗组在复发频率上没有差异。在整个研究组中，体重变化的调整估计值增加了 1.66kg（95%CI：0.83，2.48），总胆固醇变化的调整估计值降低了 14.8mg/dL（95%CI：3.5，26.1）；其余的代谢指标没有显著变化。
继续进行急性治疗与缓解期的稳定有关。
